Alkermes (ALKS) Shares Outstanding (2010 - 2026)
Alkermes (ALKS) posted quarterly Shares Outstanding (Entity) of $184.7 million for Q2 2026, up 2.36% year-over-year from $180.4 million in Q2 2025, and up 0.6% quarter-over-quarter from $183.6 million in Q1 2026.
Alkermes (ALKS) Shares Outstanding (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Shares Outstanding (Entity) for 17 consecutive years, with $184.7 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Shares Outstanding (Entity) rose 2.36% year-over-year to $184.7 million; the TTM figure through Jun 2026 stood at $184.7 million (up 2.36% YoY), while the FY2025 annual figure was $181.0 million, up 2.46% from the prior year.
- Shares Outstanding (Entity) rose to $184.7 million in Q2 2026 per ALKS's latest filing, from $183.6 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $184.7 million in Q2 2026 and bottomed at $167.7 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $175.4 million across 5 years, with a median of $175.8 million in 2024.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) advanced 1.89% — and 2025, when it gained 2.55%.
- Alkermes' Shares Outstanding (Entity) stood at $169.0 million in 2022, then gained by 2.14% to $172.6 million in 2023, then grew by 2.38% to $176.7 million in 2024, then climbed by 2.46% to $181.0 million in 2025, then advanced by 2.04% to $184.7 million in 2026.
- Business Quant data shows ALKS's Shares Outstanding (Entity) at $184.7 million in Q2 2026, $183.6 million in Q1 2026, and $181.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | 4.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 1.17 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 417.60 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 1.58 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 42.60 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 1.16 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 101.00 Mn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 499.50 Mn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | 832.44 Mn |
| 10 | Alkermes | 8.20 Bn | 7.54 Bn | 397.90 Mn | 167.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 167.03 Mn |
| Mar 31, 2026 | 166.20 Mn |
| Dec 31, 2025 | 164.70 Mn |
| Sep 30, 2025 | 165.09 Mn |
| Jun 30, 2025 | 164.96 Mn |
| Mar 31, 2025 | 163.41 Mn |
| Dec 31, 2024 | 165.39 Mn |
| Sep 30, 2024 | 163.37 Mn |
| Jun 30, 2024 | 168.32 Mn |
| Mar 31, 2024 | 167.98 Mn |
| Dec 31, 2023 | 166.22 Mn |
| Sep 30, 2023 | 166.61 Mn |
| Jun 30, 2023 | 166.28 Mn |
| Mar 31, 2023 | 165.09 Mn |
| Dec 31, 2022 | 163.54 Mn |
| Sep 30, 2022 | 164.28 Mn |
| Jun 30, 2022 | 163.84 Mn |
| Mar 31, 2022 | 162.48 Mn |
| Dec 31, 2021 | 160.94 Mn |
| Sep 30, 2021 | 161.46 Mn |